Laracor
Laracor - General Information
A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety. [PubChem]
Pharmacology of Laracor
Laracor is a non-selective beta blocker with some intrinsic sympathomimetic activity. Laracor is a lipophilic beta blocker which passes the blood-brain barrier more easily than water soluble beta blockers. As such, it is associated with a higher incidence of CNS-related side effects than hydrophilic ligands such as atenolol, sotalol and nadolol. Laracor is an potent beta-blocker and should not be administered to asthmatics because it can cause irreversible airway failure and inflammation.
Additional information about Laracor
Laracor Indication: Used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.
Mechanism Of Action: Like other beta-adrenergic antagonists, oxprenolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, oxprenolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, oxprenolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Laracor therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.
Drug Interactions: Acetohexamide The beta-blocker decreases the symptoms of hypoglycemia
Chlorpropamide The beta-blocker decreases the symptoms of hypoglycemia
Clonidine Increased hypertension when clonidine stopped
Gliclazide The beta-blocker decreases the symptoms of hypoglycemia
Glipizide The beta-blocker decreases the symptoms of hypoglycemia
Glisoxepide The beta-blocker decreases the symptoms of hypoglycemia
Glibenclamide The beta-blocker decreases the symptoms of hypoglycemia
Glycodiazine The beta-blocker decreases the symptoms of hypoglycemia
Insulin The beta-blocker decreases the symptoms of hypoglycemia
Lidocaine The beta-blocker increases the effect and toxicity of lidocaine
Repaglinide The beta-blocker decreases the symptoms of hypoglycemia
Tolbutamide The beta-blocker decreases the symptoms of hypoglycemia
Tolazamide The beta-blocker decreases the symptoms of hypoglycemia
Dihydroergotamine Ischemia with risk of gangrene
Dihydroergotoxine Ischemia with risk of gangrene
Methysergide Ischemia with risk of gangrene
Ergonovine Ischemia with risk of gangrene
Ergotamine Ischemia with risk of gangrene
Prazosin Risk of hypotension at the beginning of therapy
Verapamil Increased effect of both drugs
Epinephrine Hypertension, then bradycardia
Methyldopa Possible hypertensive crisis
Ibuprofen Risk of inhibition of renal prostaglandins
Indomethacin Risk of inhibition of renal prostaglandins
Piroxicam Risk of inhibition of renal prostaglandins
Fenoterol Antagonism
Formoterol Antagonism
Isoproterenol Antagonism
Orciprenaline Antagonism
Pirbuterol Antagonism
Practolol Antagonism
Salbutamol Antagonism
Salmeterol Antagonism
Terbutaline Antagonism
Food Interactions: Avoid alcohol.
Avoid natural licorice.
Generic Name: Oxprenolol
Synonyms: (+)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; (+-)-oxprenolol; (1)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; 1-(Isopropylamino)-2-hydroxy-3-(o-(allyloxy)phenoxy)propane; 1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)-2-propanol; 1-[2-(Allyloxy)phenoxy]-3-(isopropylamino)-2-propanol; DL-oxprenolol; Osprenololo [dcit]; Oxprenololum [inn-latin]
Drug Category: Adrenergic beta-Antagonists; Anti-anxiety Agents; Anti-Arrhythmia Agents; Antihypertensive Agents; Sympatholytics; Vasodilator Agents
Drug Type: Small Molecule; Approved
Other Brand Names containing Oxprenolol: Coretal; Laracor; Slow-pren; Trasacor; Trasicor;
Absorption: Oral bioavailability is 20-70%.
Toxicity (Overdose): Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.
Protein Binding: Not Available
Biotransformation: Hepatic.
Half Life: 1-2 hours
Dosage Forms of Laracor: Tablet Oral
Chemical IUPAC Name: 1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol
Chemical Formula: C15H23NO3
Oxprenolol on Wikipedia: https://en.wikipedia.org/wiki/Oxprenolol
Organisms Affected: Humans and other mammals
